Company Overview
HCmed Innovations Co., Ltd. (hereinafter referred to as “HCmed”) was established in 2014, with its headquarters located in Da’an District, Taipei City, Taiwan, and a GMP-certified manufacturing facility in Zhonghe District, New Taipei City.
HCmed focuses on Contract Development and Manufacturing Organization (CDMO) services for drug-specific inhalation nebulizers, providing pharmaceutical partners with end-to-end solutions—from customized high-end nebulizer design tailored to specific drugs, through development, regulatory support, and commercial manufacturing.
HCmed’s current product development comprises two main segments:
- Vibrating Mesh Nebulizers
HCmed develops vibrating mesh nebulizers that can be sold through general commercial channels and used in clinical trials for new drugs. By adjusting the membrane vibration frequency according to different drug characteristics, the nebulizer maintains optimal operating conditions during aerosolization, generating high-efficiency aerosols with particle sizes of 3–5 μm.
This enables effective delivery of medication to the lower respiratory tract without requiring patient training or specific breathing techniques. Applications include treatment of chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), and respiratory infections.
- Drug-Specific Nebulizer CDMO Services
Because inhaled drugs must be delivered through the respiratory tract, drug-device combination products are virtually the only viable development pathway for inhalation therapies. As global pharmaceutical companies increasingly concentrate resources on drug discovery and outsource delivery device development and manufacturing, CDMOs with proprietary inhalation delivery technologies have become a critical component of the inhaled drug value chain.
HCmed has long focused on CDMO services for drug-specific nebulizers and is currently one of the top three companies globally capable of providing such specialized CDMO services. The company has recently entered into multiple global development collaborations with leading international pharmaceutical companies to design and develop dedicated nebulizers for inhaled formulations of blockbuster drugs with annual sales exceeding hundreds of millions of U.S. dollars.
Technology Platform
- Intellectual Property Strategy
HCmed has actively pursued patent applications and trade secret protection for its first-generation product Deepro/Pulmogine and second-generation product AdheResp. To date, the company has established a global intellectual property portfolio comprising over 90 patents and proprietary protections.
- Micro-Synchronized Delivery Technology
Based on the physical and chemical properties of different drugs, HCmed’s technology dynamically and continuously adjusts the vibration frequency of the mesh membrane during nebulization through real-time feedback mechanisms, ensuring the membrane operates at its optimal frequency at all times.
- Breath-Actuated Detection Function
AdheResp incorporates an intra-chamber pressure differential sensing system that accurately detects the patient’s breathing pattern. Nebulization is activated during inhalation and paused during exhalation, significantly improving drug delivery efficiency and reducing waste.
- Bluetooth Connectivity
Through integrated Bluetooth connectivity, treatment data can be uploaded to enable clinicians or caregivers to remotely monitor and track patient therapy status in real time, thereby substantially enhancing treatment quality and adherence.
- High-Efficiency Drive Circuitry
HCmed addresses the high power consumption issues of traditional nebulizers, which often require stationary, plug-in use. By combining high-efficiency drive circuit design with optimized hardware architecture and microprocessor-based software control, the nebulization module operates precisely in its most energy-efficient mode, enabling portable and flexible use.
Future Outlook
As a CDMO company dedicated to inhaled drug delivery devices, HCmed leverages its innovative and proprietary nebulization platform to continuously provide patients with high-quality and affordable aerosol therapy solutions. By combining drug-specific nebulizers with strong intellectual property portfolios, HCmed enhances the competitive positioning and market value of its pharmaceutical partners’ products, driving long-term growth and value creation.